Антимикробные препараты группы фторхинолонов

1. Падейская Е.Н., Яковлев В.П. Фторхинолоны. М., Биоинформ, 1995.
2. Падейская Е.Н., Яковлев В. Антимикробные препараты группы фторхинолонов в клинической практике. М., Логата, 1998.
3. Падейская Е.Н., Яковлев В.П. Офлоксацин (таривид). Антибактериальный препарат из группы фторхинолонов. М., 1996.
4. Падейская Е.Н., Яковлев В.П. Ломефлоксацин (максаквин) – антимикробный препарат из группы фторхинолонов. М.: Универсум Паблишинг, 1998.
5. Яковлев В.П. Антибактериальная химиотерапия в неинфекционной клинике: новые бета-лактамы, монобактамы и хинолоны. Итоги науки и техники, М.: ВИНИТИ, 1992.
6. Яковлев В.П. Антибактериальные препараты группы фторхинолонов. Рус. мед. журн. Антибактериальные препараты. 1997; 5 (21): 1405–3.
7. Яковлев В.П., Падейская Е.Н., Яковлев С.В. Ципрофлоксацин в клинической практике. М.: Информэлектро, 2000.
8. Яковлев В.П., Яковлев С.В. Клиническая фармакология фторхинолонов. Обзор. Клинич. фармакология и терапия. 1994; 3 (2): 53–8.
9. Яковлев С.В. Новое поколение фторхинолонов – новые возможности лечения внебольничных инфекций дыхательных путей. Антибиотики и химиотерапия. 2001; 46 (6): 38–42.
10. Яковлев С.В. Место фторхинолонов в лечении бактериальных инфекций. Рус. мед. журнал. 2003; 11 (8): 434–7.
12. Quinolone Antimicrobial Agents. 2nd ed. Eds. D.Hooper, J.Wolfson. Washington, 1993.
13. Sorgel F, Kinzig M. Pharmacokinetics of gyrase inhibitors. Part 1: basic chemistry and gastrointestinal disposition. Amer J Med 1993; 94 (Suppl. 3A): 44–55.
14. The New Generation of Quinolones. Eds. C.Siporin, C.Heifetz, J.Damaglia. Marcel Dekker, 1990.
15. The Quinolones. Ed. V.Andriole Acad Press 1988.
16. The Quinolones. 2nd eds. Ed. V.Andriole Acad Press 1998.
17. Schito GC, Debbia EA, Marchese A. The evolving threat of antibiotic resistance in Europe new data from the Alexander PROJECT. J Antimicrob Chemother 2000; 46: Topic T1: 3–9.
18. Doern GV, Pfaller MA, Kugler K et al. Prevalence of antimicrobial resistance among respiratory tract isolates of Streptococcus pneumoniae in North America 1997 results from the SENTRY antimicrobial surveillance program. Clin Inf Dis 1998; 27: 764–70.
19. Tomono R. Pre-clinical microbiology – respiratory tract infections susceptibility survey in Japan. First Intern. Moxifloxacin Symp, Berlon 1999; Springer-Verlag. Ed. L.Mandell 2000; 67–74.
20. Appelbaum PC, Hunter PF. The fluoroquinolone antibacterials: past, present and future perspectives. Intern J Antimicrob Ag 2000; 16: 5–15.
21. Dalhoff A. In vitro activities of quinolones. Exp Opin Invect Drugs 1999; 8 (2): 123–37.
22. Gatifloxacin Scientific Monograph. Grunenthal.
23. Hammerschlag MR. Activity of gemifloxacin and other new quinolones against Chlamydia pneumoniae: a review. J Antimicrob Chemother 2000; 45 (Suppl. S1): 35–9.
24. King A, May J, French G, Phillips I. Comparative in vitro activity of gemifloxacin. J Antimicrob Chemother 2000; 45 (Suppl. S1): 1–12.
25. McCloskey L, Moore T, Niconovich N et al. In vitro activity of gemifloxacin against a broad range of recent clinical isolates from the USA. J Antimicrob Chemother 2000; 45 (Suppl. S1): 13–21.
26. Mortensen JE, Rodgers GL. In vitro activity of gemifloxacin and other antimicrobial agents against isolates of Bordetella pertussis and Bordetella parapertussis. J Antimicrob Chemother 2000; 45 (Suppl. S1): 47–9.
27. Rittenhouse S, McCloskey L, Broskey J et al. In vitro antibacterial activity of gemifloxacin and comparator compounds against common respiratory pathogens. J Antimicrob Chemother 2000; 45 (Suppl. S1): 23–7.
28. Soussy CJ, Debeugny B, Akalin HE et al. Comparative international study of sparfloxacin in vitro activity against 7 respiratory tract pathogens. – 35th Int Conf Antimicrob Ag Chemother, San Francisco 1995. Abstracts: Е133.
29. Goldstein EJC. Review of the in vitro activity of gemifloxacin against Gram-positive and Gram-negative anaerobic pathogens. J Antimicrob Chemother 2000; 45 (Suppl. S1): 55–65.
30. MacGowan AP, Bowker KE, Holt HA et al. BAY 12-8039, a new 8-methoxyquinolone: comparative in vitro activity with nine other antimicrobials against anaerobic bacteria. J Antimicrob Chemother 1997; 40: 503–9.
31. Яковлев В.П., Яковлев С.В. Моксифлоксацин. Новый антимикробный препарат из группы фторхинолонов. М.: Информэлектро, 2002.
32. Avelox. Moxifloxacin hydrochlorid. Monograpn. Bayer 2000.
33. Andrews J, Khair O, Honeybourne D et al. Concentrations of gemifloxacin in potential sites of respiratory infection in patients following once-daily 320 mg dosing for 4 days prior to diagnostic bronchoscopy. 12th Eur Congr Clin Microb Inf Dis, Milan, 2002; Abstracts: P755. Clin Microb Inf 2002; 8: Suppl. 1.
34. Fogarty C, Grossman C, Williams J et al. Efficacy and safety of moxifloxacin vs clarithromyin for community-acquired pneumonia. Inf Med 1999; 16 (11): 748–63.
35. Hoeffken G, Meyer HP, Winter J et al. The efficacy and safety of two oral moxifloxacin regimens compared to oral clarithromycin in the treatment of community-acquired pneumonia. Resp Med 2001; 95: 1–12.
36. Springsklee M. Clinical needs in the millennium – pneumoniae – the role of moxifloxacin. – 1st Intern. Moxifloxacin Symp, Berlin, 1999. Ed. Mandell L.Springer-Verlag, 2000; 154–8.
37. Church D. Clinical needs in the millennium – acute exacerbations of chronic bronchitis – the role of moxifloxacin. 1st Int Moxifloxacin Symp, Berlin 1999. Ed. L.Mandell, Springer-Verlag 2000; 166–8.
38. Schaberg T. Comparative effect of moxifloxacin and co-amoxiclav in the treatment of AECB. – 10th Eur Congr Clin Microbiol Inf Dis, Stockholm, 2000. Abstracts: N WeP 236. Clin Microbiol Inf 2000; 6: suppl. 1.
39. Burke T, Villanueva C, Mariano H et al. Comparison of moxifloxacin and cefuroxime axetil in the treatment of acute maxillary sinusitis. Clin Therap 1999; 21 (10): 1664–77.
40. Hampel B. Clinical needs in the millennium – rhinosinusitis – the role of moxifloxacin. 1st Intern Moxifloxacin Symp, Berlin 1999. Ed. Mandell L.Springer-Verlag 2000; 174–7.
41. Carbon C. Clinical efficacy and safety of levofloxacin for mild-to-moderate community-acquired pneumonia. In: Penetration. Int Update on Levofloxacin and Ofloxacin, Biomedis, Tokyo 2002; 37–41.
42. Erard VA, Bochud PY, Cometta A et al. Full course oral levofloxacin vs. intravenous (ceftriaxone +/- clarithromycin)-tо-oral sequential antibiotic therapy for patients hospitalised with community-acquired pneumonia (CAP). 41st Intersci Conf Antimicrob Ag Chemother, Chicago 2001. Abstracts: NL-870.
43. File TM. Levofloxacin in the treatment of community-acquired pneumonia. Clin Respir J 1999; 6 (Suppl. A): 35A–39A.
44. Burley CJ, Masterton RG. A double-blind comparison of oral levofloxacin 500 mg once daily for 7 days in patients with acute exacerbation of chronic bronchitis. 9th Eur Congr Clin Micr Inf Dis, Berlin 1999. Abs. P715. Clin Micr Inf 1999; 5 (Suppl. 3): 276.
45. DeAbate CA. Levofloxacin – the «respiratory fluoroquinolone». Penetration Intern Update on Levofloxacin and Ofloxacin. Biomedis, Tokyo 1998; p. 5–10.
46. Habib MP, Gentry LO, Rodriguez-Gomez G et al. A multicenter, randomized study comparing the efficacy and safety of oral levofloxacin vs cefaclor in the treatment of acute bacterial exacerbations of chronic bronchitis. Penetratiobn Int Update Levofloxacin and Ofloxacin. Biomedis, Tokyo 1998; 13.
47. Urueta J, Ariza H, De Brito J et al. Safety and efficacy of moxifloxacin vs levofloxacin in the teatment of AECB. 11th Eur Congr Clin Microbiol If Dis, Istanbul 2001; Abstracts P864. Clin Microbiol Inf 2001; 7: suppl. 1.
48. Adelglass J, Jones TM, Ruoff G et al. A multicenter, investigator-blinded, randomized comparison of oral levofloxacin and oral clarithromycin in the treatment of acute bacterial sinusitis. Pharmacotherapy 1998; 18 (6): 1255–63.
49. Gehanno P and French Sinusitis Group. Otral levofloxacin, 500 mg once daily, in the treatment of acute maxillary sinusitis in adults. 7th Biebiennial Conf Antiinf Ag Chemother and 2nd Eur Congr Chemother, Hamburg, 1998; Abstracts: T-106. Antiinf Drugs Chemother 1998; 16: suppl. 1.
50. Sydnor TA. Levofloxacin – an extremely useful drug in the treatment of sinusitis. Penetration: Int Update on Levofloxacin and Ofloxacin. Ann Iissue 1997; Biomedis, Tokyo, 16–20.
51. Finch R, Colins O, Kubin R et al. Moxifloxacin IV/PO compared with amoxicillin/clavulanate IV/PO with or without clarithromycin in the treatment of community-acquired pneumonia. Clin Microbiol Inf 2001; 7 (Suppl. 1): 167.
52. Querol-Ribelles JM, Tenias JM, Querol-Borras JM et al. Levofloxacin versus ceftriaxon plus clarithromycin in the treatment of adults with community-acquired pneumonia requiring hospitalization. Int J Antimicrob Agents 2005; 25 (1): 75–83.
53. Hepburn MJ, Dooley DP, Skidmore PJ et al. Comparison of short-course (5 days) and standart (10 days) treatment for uncomplicated cellulites. Arch Intern Med 2004; 164 (15):1669–74.
54. Graham DR, Talan DA, Nichols RL et al. Once-daily, high-dose levofloxacin versus ticarcillin-clavulanate alone or followed by amoxicillin-clavulanate for complicated skin and skin-structure infections: a randomized, open-label trial. Clin Inf Dis 2002; 35 (4): 381–9.
55. Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a multicenter, prospective, randomized, open-label study. Clin Ther 2003; 25 (2): 485–506.
56. Shorr AF, Zadeikis N, Jackson WL et al. Levofloxacin for treatment of ventilator-associated pneumonia: a subgroup analysis from a randomized trial. Clin Infect Dis 2005; 40 (Suppl 2): S123–129.
57. Ball P. Quinolone generations: natural history or natural selection? J Antimicrob Chemother 2000; 46: Topic T1: 17–24.

В.П.Яковлев 

Институт хирургии им. А.В.Вишневского РАМН, Москва